NBAtlas: A harmonized single-cell transcriptomic reference atlas of human neuroblastoma tumors. Bonine N, Zanzani V, Van Hemelryk A, Vanneste B, Zwicker C, Thoné T, Roelandt S, Bekaert SL, Koster J, Janoueix-Lerosey I, Thirant C, Van Haver S, Roberts SS, Mus LM, De Wilde B, Van Roy N, Everaert C, Speleman F, Vermeirssen V, Scott CL, De Preter K. Cell Rep. 2024 Oct 22;43(10):114804. doi: 10.1016/j.celrep.2024.114804. Epub 2024 Oct 3.PMID: 39368085

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia.  Almeida A, T’Sas S, Pagliaro L, Fijalkowski I, Sleeckx W, Van Steenberge H, Zamponi R, Lintermans B, Van Loocke W, Palhais B, Reekmans A, Bardelli V, Demoen L, Reunes L, Deforce D, Van Nieuwerburgh F, Kentsis A, Ntziachristos P, Van Roy N, De Moerloose B, Mecucci C, La Starza R, Roti G, Goossens S, Van Vlierberghe P, Pieters T. Hemasphere. 2024 Mar 10;8(3):e51. doi: 10.1002/hem3.51. eCollection 2024 Mar. PMID: 38463444

Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma. De Coninck S, De Smedt R, Lintermans B, Reunes L, Kosasih HJ, Reekmans A, Brown LM, Van Roy N, Palhais B, Roels J, Van der Linden M, Van Dorpe J, Ntziachristos P, Van Delft FW, Mansour MR, Pieters T, Lammens T, De Moerloose B, De Bock CE, Goossens S, Van Vlierberghe P. Haematologica. 2024 May 1;109(5):1373-1384. doi: 10.3324/haematol.2023.283981. PMID: 37941480

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma. Provez L, Putteman T, Landfors M, Roels J, Reunes L, T’Sas S, Van Loocke W, Lintermans B, De Coninck S, Thenoz M, Sleeckx W, Maćkowska-Maślak N, Taghon T, Mansour MR, Farah N, Norga K, Vandenberghe P, Kotecha RS, Goossens S, Degerman S, De Smedt R, Van Vlierberghe P. Cancers (Basel). 2023 Jan 20;15(3):647. doi: 10.3390/cancers15030647. PMID: 36765607

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. Nunes C, Depestel L, Mus L, Keller KM, Delhaye L, Louwagie A, Rishfi M, Whale A, Kara N, Andrews SR, Dela Cruz F, You D, Siddiquee A, Cologna CT, De Craemer S, Dolman E, Bartenhagen C, De Vloed F, Sanders E, Eggermont A, Bekaert SL, Van Loocke W, Bek JW, Dewyn G, Loontiens S, Van Isterdael G, Decaesteker B, Tilleman L, Van Nieuwerburgh F, Vermeirssen V, Van Neste C, Ghesquiere B, Goossens S, Eyckerman S, De Preter K, Fischer M, Houseley J, Molenaar J, De Wilde B, Roberts SS, Durinck K, Speleman F. Sci Adv. 2022 Jul 15;8(28):eabn1382. doi: 10.1126/sciadv.abn1382. Epub 2022 Jul 13. PMID: 35857500

Direct and indirect anti-leukemic properties of activity-on-target interferons for the treatment of T-cell acute lymphoblastic leukemia. Goossens S, Cauwels A, Pieters T, De Smedt R, T’Sas S, Almeida A, Daneels W, Van Vlierberghe P, Tavernier J. Haematologica. 2022 Jun 1;107(6):1448-1453. doi: 10.3324/haematol.2021.278913. PMID: 34647441

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.  Pieters T, T’Sas S, Vanhee S, Almeida A, Driege Y, Roels J, Van Loocke W, Daneels W, Baens M, Marchand A, Van Trimpont M, Matthijssens F, Morscio J, Lemeire K, Lintermans B, Reunes L, Chaltin P, Offner F, Van Dorpe J, Hochepied T, Berx G, Beyaert R, Staal J, Van Vlierberghe P, Goossens S. J Exp Med. 2021 Oct 4;218(10):e20202280. doi: 10.1084/jem.20202280. Epub 2021 Aug 18. PMID: 34406363

The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL. Di Grande A, Peirs S, Donovan PD, Van Trimpont M, Morscio J, Lintermans B, Reunes L, Vandamme N, Goossens S, Nguyen HA, Lavie A, Lock RB, Prehn JHM, Van Vlierberghe P, Ní Chonghaile T. Blood Adv. 2021 Apr 13;5(7):1963-1976. doi: 10.1182/bloodadvances.2021004177. PMID: 33830207

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. Matthijssens F, Sharma ND, Nysus M, Nickl CK, Kang H, Perez DR, Lintermans B, Van Loocke W, Roels J, Peirs S, Demoen L, Pieters T, Reunes L, Lammens T, De Moerloose B, Van Nieuwerburgh F, Deforce DL, Cheung LC, Kotecha RS, Risseeuw MD, Van Calenbergh S, Takarada T, Yoneda Y, van Delft FW, Lock RB, Merkley SD, Chigaev A, Sklar LA, Mullighan CG, Loh ML, Winter SS, Hunger SP, Goossens S, Castillo EF, Ornatowski W, Van Vlierberghe P, Matlawska-Wasowska K. J Clin Invest. 2021 Mar 15;131(6):e141566. doi: 10.1172/JCI141566. PMID: 33555272

Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia.  Roels J, Thénoz M, Szarzyńska B, Landfors M, De Coninck S, Demoen L, Provez L, Kuchmiy A, Strubbe S, Reunes L, Pieters T, Matthijssens F, Van Loocke W, Erarslan-Uysal B, Richter-Pechańska P, Declerck K, Lammens T, De Moerloose B, Deforce D, Van Nieuwerburgh F, Cheung LC, Kotecha RS, Mansour MR, Ghesquière B, Van Camp G, Berghe WV, Kowalczyk JR, Szczepański T, Davé UP, Kulozik AE, Goossens S, Curtis DJ, Taghon T, Dawidowska M, Degerman S, Van Vlierberghe P. Blood Cancer Discov. 2020 Nov;1(3):274-289. doi: 10.1158/2643-3230.BCD-20-0059. Epub 2020 Sep 23.PMID: 33179015

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies. Pieters T, T’Sas S, Demoen L, Almeida A, Haenebalcke L, Matthijssens F, Lemeire K, D’Hont J, Van Rockeghem F, Hochepied T, Lintermans B, Reunes L, Lammens T, Berx G, Haigh JJ, Goossens S, Van Vlierberghe P. Sci Rep. 2019 Jul 22;9(1):10577. doi: 10.1038/s41598-019-46853-x.PMID: 31332244

Vehicle development, pharmacokinetics and toxicity of the anti-invasive agent 4-fluoro-3′,4′,5′-trimethoxychalcone in rodents. Mus LM, Denecker G, Speleman F, Roman BI. PLoS One. 2018 Feb 22;13(2):e0192548. doi: 10.1371/journal.pone.0192548. eCollection 2018. PMID: 29470507

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples. Van Goethem A, Yigit N, Everaert C, Moreno-Smith M, Mus LM, Barbieri E, Speleman F, Mestdagh P, Shohet J, Van Maerken T, Vandesompele J. Sci Rep. 2016 Nov 30;6:37876. doi: 10.1038/srep37876. PMID: 27901112